Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) following the Company's announcement of topline results from its Phase III Orbit and Cosmic Studies, focusing on the effectiveness of setrusumab (UX143) on Osteogenesis Imperfecta. Investors with concerns about Ultragenyx's business operations may click here for more information. Ultragenyx reported the study results on December 29, 2025. Both studies failed to achieve their primary ...